Otsuka Holdings has won FDA approval for a version of its commonly prescribed Abilify that includes a digestible sensor made by Proteus. The first-of-its-kind approval will allow patients who are taking Abilify for schizophrenia or bipolar disorder to share information the sensor collects with their healthcare provider through a wearable patch and a smartphone application.